secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2026-07-16T11:53:02+00:00
Accession:  0001104659-26-084086
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics updates cash runway; expects funding into Q2 2027
-------------------------------------------------------------------

- Cash and equivalents expected to fund operations into Q2 2027 based on current plans.
- Phase 1b open-label extension completion expected in October 2026.
- Phase 2 clinical study initiation planned for Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926084086/0001104659-26-084086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926084086/tm2620618d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-084086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer